JP6370490B2 - 免疫抑制活性なしに神経再生活性が維持されるｆｋ５０６誘導体及びその用途 - Google Patents

免疫抑制活性なしに神経再生活性が維持されるｆｋ５０６誘導体及びその用途 Download PDF

Info

Publication number
JP6370490B2
JP6370490B2 JP2017526030A JP2017526030A JP6370490B2 JP 6370490 B2 JP6370490 B2 JP 6370490B2 JP 2017526030 A JP2017526030 A JP 2017526030A JP 2017526030 A JP2017526030 A JP 2017526030A JP 6370490 B2 JP6370490 B2 JP 6370490B2
Authority
JP
Japan
Prior art keywords
deoxo
prolyl
streptomyces
activity
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017526030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523241A (ja
Inventor
ジョオン ヨオン イエオ
ジョオン ヨオン イエオ
ジェオング クウオン ホ
ジェオング クウオン ホ
ヘエ バン イエオン
ヘエ バン イエオン
プラモドブ シンデ
プラモドブ シンデ
Original Assignee
イントロン バイオテクノロジー シーオー．，エルティーディー
イントロン バイオテクノロジー シーオー．，エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イントロン バイオテクノロジー シーオー．，エルティーディー, イントロン バイオテクノロジー シーオー．，エルティーディー filed Critical イントロン バイオテクノロジー シーオー．，エルティーディー
Publication of JP2017523241A publication Critical patent/JP2017523241A/ja
Application granted granted Critical
Publication of JP6370490B2 publication Critical patent/JP6370490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2017526030A 2014-08-01 2015-07-31 免疫抑制活性なしに神経再生活性が維持されるｆｋ５０６誘導体及びその用途 Active JP6370490B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2014-0099210 2014-08-01
KR1020140099210A KR101694879B1 (ko) 2014-08-01 2014-08-01 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
PCT/KR2015/008031 WO2016018117A1 (ko) 2014-08-01 2015-07-31 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018012496A Division JP6851334B2 (ja) 2014-08-01 2018-01-29 免疫抑制活性なしに神経再生活性が維持されるｆｋ５０６誘導体及びその用途

Publications (2)

Publication Number Publication Date
JP2017523241A JP2017523241A (ja) 2017-08-17
JP6370490B2 true JP6370490B2 (ja) 2018-08-08

Family

ID=55217893

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017526030A Active JP6370490B2 (ja) 2014-08-01 2015-07-31 免疫抑制活性なしに神経再生活性が維持されるｆｋ５０６誘導体及びその用途
JP2018012496A Active JP6851334B2 (ja) 2014-08-01 2018-01-29 免疫抑制活性なしに神経再生活性が維持されるｆｋ５０６誘導体及びその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018012496A Active JP6851334B2 (ja) 2014-08-01 2018-01-29 免疫抑制活性なしに神経再生活性が維持されるｆｋ５０６誘導体及びその用途

Country Status (6)

Country Link
US (2) US10226446B2 (https=)
EP (1) EP3187183B1 (https=)
JP (2) JP6370490B2 (https=)
KR (1) KR101694879B1 (https=)
CN (2) CN106794169B (https=)
WO (1) WO2016018117A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
US12011497B2 (en) * 2018-12-11 2024-06-18 Molgenbio Co. Ltd. Compounds, compositions containing same, and use thereof for promoting hair growth
US11449807B2 (en) 2020-01-31 2022-09-20 Walmart Apollo, Llc Systems and methods for bootstrapped machine learning algorithm training
JP7542876B2 (ja) * 2020-06-19 2024-09-02 モルジェンバイオ・カンパニー・リミテッド 神経突起成長及びシナプス形成活性を持つ新規プロリルｆｋ５０６誘導体及びその用途
CN118460433B (zh) * 2024-06-04 2026-01-06 浙江启臻合成生物技术有限公司 生产他克莫司的链霉菌工程菌及其构建方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
EP1595541A1 (en) * 2004-05-12 2005-11-16 Alcasynn Pharmaceuticals Gmbh Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
CN101573109A (zh) * 2006-12-28 2009-11-04 利默里克生物制药公司 用于治疗的方法和组合物
WO2009158031A2 (en) * 2008-06-27 2009-12-30 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
KR101261131B1 (ko) * 2010-08-24 2013-05-06 이화여자대학교 산학협력단 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주
KR101632042B1 (ko) * 2014-06-30 2016-06-21 주식회사 인트론바이오테크놀로지 Fk506 유도체를 함유하는 크립토코쿠스 속 곰팡이 및 칸디다 속 곰팡이에 의한 진균 감염을 치료하기 위한 약제학적 조성물 및 그의 용도
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도

Also Published As

Publication number Publication date
EP3187183B1 (en) 2020-04-08
US10576060B2 (en) 2020-03-03
JP6851334B2 (ja) 2021-03-31
KR20160017267A (ko) 2016-02-16
JP2017523241A (ja) 2017-08-17
US20190134001A1 (en) 2019-05-09
EP3187183A1 (en) 2017-07-05
JP2018083843A (ja) 2018-05-31
EP3187183A4 (en) 2018-03-21
CN106794169B (zh) 2020-02-04
US20170216254A1 (en) 2017-08-03
KR101694879B1 (ko) 2017-01-12
WO2016018117A1 (ko) 2016-02-04
CN106794169A (zh) 2017-05-31
US10226446B2 (en) 2019-03-12
CN110251511A (zh) 2019-09-20

Similar Documents

Publication Publication Date Title
JP6851334B2 (ja) 免疫抑制活性なしに神経再生活性が維持されるｆｋ５０６誘導体及びその用途
Huang et al. Antimalarial β-carboline and indolactam alkaloids from Marinactinospora thermotolerans, a deep sea isolate
KR101599982B1 (ko) 노노무라에아 종으로부터의 고리형 펩티드, 그에 대한 생산 프로세스 및 이를 포함하는 마이코박테리아 관련 질병의 치료 혹은 예방을 위한 약학적 조성물
Stierle et al. Caspase-1 and-3 inhibiting drimane sesquiterpenoids from the extremophilic fungus Penicillium solitum
KR101261131B1 (ko) 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주
Ji et al. Macrocyclic nonapeptides incorporating uncharacterized amino acids with inhibitory effects on Th17 differentiation
Son et al. Polyketides and anthranilic acid possessing 6-deoxy-α-L-talopyranose from a Streptomyces Species
CN103857400A (zh) 玫瑰红景天提取物和分离的化合物及其在治疗神经变性疾病中的应用
He et al. Penicipyrrolidines A− N, pyrrolidine derivatives with inhibitory effects on EMT and fibroblast activation from the mangrove-derived fungus Penicillium sp. DM27
Summers et al. 3-normeridamycin: a potent non-immunosuppressive immunophilin ligand is neuroprotective in dopaminergic neurons
KR101723869B1 (ko) 디히드로이소쿠마린 유도체를 함유하는 염증 질환 예방 또는 치료용 약학 조성물
KR102134782B1 (ko) 신규 화합물 및 이를 포함하는 신경계 질환 치료용 약학적 조성물
Shinde et al. A non-immunosuppressive FK506 analogue with neuroregenerative activity produced from a genetically engineered Streptomyces strain
KR20160067079A (ko) 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
Kim et al. Discovery of 15-deoxynaphthomycins activating the antioxidant NRF2-ARE pathway from Streptomyces sp. N50 via genome mining, global regulator introduction, and molecular networking
CN115916787B (zh) 具有神经突生长和突触形成活性的新型脯氨酰fk506衍生物及其用途
KR20240099949A (ko) Pseudogymnoascus sp. SF-7351 유래 마크로스펠라이드의 신규한 용도
Agatonovic-Kustrin et al. Structural characteristics of bioactive marine natural products
US20220112180A1 (en) Novel compounds as potential therapeutic agents targeting various neurodegenerative diseases
Abdelgawwad {" _content_"=>" New Cytotoxic Cyclic Peptide from the Marine Sponge-Associated sp. UR67."," i"=>{" _content_"=>" Nocardiopsis"}}
Pérez-Bonilla et al. Kronopolitides A–F, a Family of 36-Membered Polyol Macrolides with Antiparasitic Activity against Chagas Disease
KR20250165858A (ko) Staphylococcus xylosus로부터 분리한 신규 피라지논 유도체 및 이의 용도
Noguez Chemical investigation of the Antarctic marine invertebrates Synoicum adareanum and Artemisina plumosa
Han Natural products studies of the marine cyanobacteria Lyngbya semiplena and Lyngbya majuscula
Brastianos Bioactive natural products from nature

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170222

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170131

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180626

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180710

R150 Certificate of patent or registration of utility model

Ref document number: 6370490

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250